People · Operator
Named in public records as an officer, director or promoter · active 2012–2021 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Inflammatix, Inc. | — | Biotechnology | Series D+ | $134.5M | $3.3B | 2020 |
| GeneWeave Biosciences, Inc. | — | Biotechnology | Series A | $36.3M | $441.0M | 2012 |
Steven Tablak at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Steven Tablak on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Michael Rubin | 1 | 8 |
| Justin Kao | 1 | 4 |
| Xiangmin Cui | 1 | 3 |
| Ted Driscoll | 1 | 2 |
| TIMOTHY SWEENEY | 1 | 2 |
| Min Cui, Ph.D. | 1 | 1 |
| Diego Rey | 1 | 1 |
| Nora Bianchi | 1 | 1 |
| Leonardo Teixeira | 1 | 1 |
| KENNETH BAHK | 1 | 1 |
| DAVID PERSING | 1 | 1 |
| JONATHAN ROMANOWSKY | 1 | 1 |
| Kenneth Bahk, Ph.D. | 1 | 1 |
| Werner Frei | 1 | 1 |
| Jason Springs | 1 | 1 |
| Ted Driscoll, Ph.D. | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.